Applied BioCode Corporation (6598.TW)

TWD 20.35

(-0.97%)

Net Debt Summary of Applied BioCode Corporation

Applied BioCode Corporation's latest annual net debt in 2023 was -378.76 Million TWD , up 51.58% from previous year.
Applied BioCode Corporation's latest quarterly net debt in 2024 Q2 was -427.45 Million TWD , up 6.57% from previous quarter.
Applied BioCode Corporation reported annual net debt of -782.21 Million TWD in 2022, down -33.18% from previous year.
Applied BioCode Corporation reported annual net debt of -587.31 Million TWD in 2021, up 25.32% from previous year.
Applied BioCode Corporation reported quarterly net debt of -457.53 Million TWD for 2024 Q1, down -20.8% from previous quarter.
Applied BioCode Corporation reported quarterly net debt of -378.76 Million TWD for 2023 Q4, up 17.61% from previous quarter.

Annual Net Debt Chart of Applied BioCode Corporation (2023 - 2012)

Historical Annual Net Debt of Applied BioCode Corporation (2023 - 2012)

Year	Net Debt	Net Debt Growth
2023	-378.76 Million TWD	51.58%
2022	-782.21 Million TWD	-33.18%
2021	-587.31 Million TWD	25.32%
2020	-786.48 Million TWD	-368.2%
2019	-167.97 Million TWD	50.67%
2018	-340.52 Million TWD	-37.76%
2017	-247.18 Million TWD	-346.45%
2016	-55.36 Million TWD	58.97%
2015	-134.94 Million TWD	33.42%
2014	-202.66 Million TWD	-397.02%
2013	-40.77 Million TWD	70.99%
2012	-140.53 Million TWD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	-427.45 Million TWD	6.57%
2024 Q1	-457.53 Million TWD	-20.8%
2023 Q4	-378.76 Million TWD	17.61%
2023 FY	-378.76 Million TWD	51.58%
2023 Q2	-484.51 Million TWD	11.19%
2023 Q3	-459.74 Million TWD	5.11%
2023 Q1	-545.58 Million TWD	30.25%
2022 Q1	-591.05 Million TWD	-0.64%
2022 Q2	-826.57 Million TWD	-39.85%
2022 Q4	-782.21 Million TWD	9.37%
2022 Q3	-863.06 Million TWD	-4.41%
2022 FY	-782.21 Million TWD	-33.18%
2021 FY	-587.31 Million TWD	25.32%
2021 Q3	-657.52 Million TWD	4.36%
2021 Q4	-587.31 Million TWD	10.68%
2021 Q1	-761.34 Million TWD	3.2%
2021 Q2	-687.53 Million TWD	9.7%
2020 Q1	-93.61 Million TWD	44.27%
2020 Q2	-874.35 Million TWD	-834.02%
2020 Q3	-513.55 Million TWD	41.26%
2020 Q4	-786.48 Million TWD	-53.14%
2020 FY	-786.48 Million TWD	-368.2%
2019 Q1	350.56 Million TWD	202.95%
2019 FY	-167.97 Million TWD	50.67%
2019 Q3	-219.54 Million TWD	-493.01%
2019 Q2	55.86 Million TWD	-84.07%
2019 Q4	-167.97 Million TWD	23.49%
2018 Q2	-120.15 Million TWD	0.0%
2018 FY	-340.52 Million TWD	-37.76%
2018 Q4	-340.52 Million TWD	0.0%
2018 Q1	-120.15 Million TWD	51.39%
2017 FY	-247.18 Million TWD	-346.45%
2017 Q2	-32.72 Million TWD	0.0%
2017 Q1	-32.72 Million TWD	40.9%
2017 Q3	-247.18 Million TWD	-655.4%
2017 Q4	-247.18 Million TWD	0.0%
2016 Q2	-236.04 Million TWD	0.0%
2016 Q4	-55.36 Million TWD	0.0%
2016 FY	-55.36 Million TWD	58.97%
2015 FY	-134.94 Million TWD	33.42%
2015 Q4	-134.94 Million TWD	0.0%
2014 FY	-202.66 Million TWD	-397.02%
2013 FY	-40.77 Million TWD	70.99%
2012 FY	-140.53 Million TWD	0.0%

Peer Net Debt Comparison of Applied BioCode Corporation

Name	Net Debt	Net Debt Difference
Excelsior Medical Co., Ltd.	-1.17 Billion TWD	67.663%
Apex Medical Corp.	-283.82 Million TWD	-33.449%
OK Biotech Co., Ltd.	9.94 Million TWD	3909.726%